Literature DB >> 33846517

Triage of human papillomavirus infected women by methylation analysis in first-void urine.

Severien Van Keer1, Annina P van Splunter2, Jade Pattyn3, Annemie De Smet3, Sereina A Herzog4, Xaveer Van Ostade5, Wiebren A A Tjalma6,7, Margareta Ieven8, Pierre Van Damme3, Renske D M Steenbergen2, Alex Vorsters3.   

Abstract

Host cell DNA methylation analysis in urine provides promising triage markers for women diagnosed with a high-risk (HR) human papillomavirus (HPV) infection. In this study, we have investigated a panel of six host cell methylation markers (GHSR, SST, ZIC1, ASCL1, LHX8, ST6GALNAC5) in cervicovaginal secretions collected within the first part of the urine void (FVU) from a referral population. Cytology, histology, and HPV DNA genotyping results on paired FVU and cervical samples were available. Urinary median methylation levels from HR-HPV (n = 93) positive women were found to increase for all markers with severity of underlying disease. Significantly elevated levels were observed for GHSR and LHX8 in relation to high-grade cervical intraepithelial neoplasia (CIN2 +; n = 33), with area under de curve values of 0.80 (95% Confidence Interval (CI) 0.59-0.92) and 0.76 (95% CI 0.58-0.89), respectively. These findings are the first to support the assertion that methylation analysis of host cell genes is feasible in FVU and holds promise as molecular, triage strategy to discern low- from high-grade cervical disease in HR-HPV positive women. Molecular testing on FVU may serve to increase cervical cancer screening attendance in hard-to-reach populations whilst reducing loss to follow-up and await further optimization and validation studies.

Entities:  

Year:  2021        PMID: 33846517     DOI: 10.1038/s41598-021-87329-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

1.  Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer.

Authors:  V Senkomago; A C Des Marais; L Rahangdale; C R T Vibat; M G Erlander; J S Smith
Journal:  J Clin Virol       Date:  2015-11-06       Impact factor: 3.168

2.  Barriers to cervical cancer screening attendance in England: a population-based survey.

Authors:  Jo Waller; Marta Bartoszek; Laura Marlow; Jane Wardle
Journal:  J Med Screen       Date:  2009       Impact factor: 2.136

3.  Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.

Authors:  Nicole J Polman; Renée M F Ebisch; Daniëlle A M Heideman; Willem J G Melchers; Ruud L M Bekkers; Anco C Molijn; Chris J L M Meijer; Wim G V Quint; Peter J F Snijders; Leon F A G Massuger; Folkert J van Kemenade; Johannes Berkhof
Journal:  Lancet Oncol       Date:  2019-01-15       Impact factor: 41.316

4.  Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Authors:  J W Sellors; A T Lorincz; J B Mahony; I Mielzynska; A Lytwyn; P Roth; M Howard; S Chong; D Daya; W Chapman; M Chernesky
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

Review 5.  Interventions targeted at women to encourage the uptake of cervical screening.

Authors:  Thomas Everett; Andrew Bryant; Michelle F Griffin; Pierre Pl Martin-Hirsch; Carol A Forbes; Ruth G Jepson
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

6.  HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.

Authors:  A Leeman; M Del Pino; A Molijn; A Rodriguez; A Torné; M de Koning; J Ordi; F van Kemenade; D Jenkins; W Quint
Journal:  BJOG       Date:  2017-08       Impact factor: 6.531

7.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

Authors:  Marc Arbyn; Sara B Smith; Sarah Temin; Farhana Sultana; Philip Castle
Journal:  BMJ       Date:  2018-12-05

8.  Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening.

Authors:  Alex Sargent; Samantha Fletcher; Katarina Bray; Henry C Kitchener; Emma J Crosbie
Journal:  BMJ Open       Date:  2019-04-29       Impact factor: 2.692

9.  Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.

Authors:  Mette Tranberg; Jørgen Skov Jensen; Bodil Hammer Bech; Berit Andersen
Journal:  BMC Infect Dis       Date:  2020-12-04       Impact factor: 3.090

10.  Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples.

Authors:  Severien Van Keer; Wiebren A A Tjalma; Jade Pattyn; Samantha Biesmans; Zoë Pieters; Xaveer Van Ostade; Margareta Ieven; Pierre Van Damme; Alex Vorsters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-07       Impact factor: 3.267

View more
  1 in total

Review 1.  Epigenetic and Transcriptomic Regulation Landscape in HPV+ Cancers: Biological and Clinical Implications.

Authors:  Rosario Castro-Oropeza; Patricia Piña-Sánchez
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.